Global Inhaled Antibiotics Market Size & Share to 2027

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,950	165 Pages	QualiKet Research	April, 2022	QUA17148449

Best Price Guarantee
Price	from $3,950
Length	165 Pages
Publisher	QualiKet Research
Published Date	April, 2022
SKU	QUA17148449

Global Inhaled Antibiotics Market Size & Share to 2027

Global Inhaled Antibiotics Market Size, Trends & Growth Opportunity, By Product Type (Aerosol, Dry Powder Formulation, and Spray), By Application (Pneumonia, Asthma, Bronchitis, and Others), By Distribution Channel, By Region and Forecast till 2027

Global Inhaled Antibiotics Market

Inhaled antibiotics are used to respiratory tract infections. Patients are suffering from chronic respiratory diseases like cystic fibrosis (CF) and non-CF bronchiectasis may be affected complex infections, by Methicillin-resistant Staphylococcus aureus, and by Pseudomonas aeruginosa. Inhaled antibiotics have several advantages such as it can deliver high concentrations drug at place of infection without the systematic unfavorable effects. The main application of inhaled antibiotics is to enhance drug delivery to the target site of infection.

Market Drivers

The rise in incidences of respiratory diseases such as asthma, COPD (Chronic obstructive pulmonary diseases), and bronchitis is expected to propel the global inhaled antibiotics market growth. For instance, as per the WHO report, 2020 asthma is common disease among children across the world and around 339 million people are suffering from asthma in 2016. Furthermore, as per the WHO data around 251 million cases of COPD were registered globally in 2016. Moreover,, rise in product launch activities as well as new product approvals will propel the global inhaled antibiotics market growth. For instance, in October 2017, Polyphor had launched an inhaled antibiotic murepavadin. It is type of outer membrane protein targeting antibiotic. It is specifically acts against the bacterial strain Pseudomonas aeruginosa. In addition to that, in February 2016 Teva Canada Limited had received approval from Health Canada for its generic solution called as PrTeva-Tobramycin Inhalation Solution. This solution used for the treatment of cystic fibrosis.

Market Restraints

The side effects associated with drug inhalation and unattainability of single effective inhaler are some restraining factors which are expected to limit the global inhaled antibiotics market growth. Cough, wheezing, hemoptysis and dyspnea are most common side effects caused by inhaled antibiotics.

Market Segmentation

Global Inhaled Antibiotics Market is segmented into product type Aerosol, Dry Powder Formulation, and Spray, by application such as Pneumonia, Asthma, Bronchitis, and Others. Further, market is segmented into distribution channel such as Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.

Also, Global Inhaled Antibiotics Market is segmented five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Market Key Players

Various key players are listed in this report such as Lupin Ltd, Polyphor, Aradigm, Gilead Sciences, Insmed Incorporated, Pharmaero, Joincare Pharmaceutical Group, Savara Pharmaceuticals,and Pharmaxis Ltd

Market Taxonomy

By Product Type

Aerosol
Dry Powder Formulation
Spray

By Application

Pneumonia
Asthma
Bronchitis
Others

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Key Questions Addressed by the Report

What are the Key Opportunities in Global Inhaled Antibiotics Market?
What will be the growth rate from 2019 to 2027?
Which segment/region will have highest growth?
What are the factors that will impact/drive the Market?
What is the competitive Landscape in the Industry?
What is the role of key players in the value chain?
What are the strategies adopted by key players?

1 Introduction: 1.1 Objective of the Study; 1.2 Market Definition; 1.3 Market Scope
2 Research Methodology: 2.1 Data Mining; 2.2 Validation; 2.3 Primary Interviews; 2.4 List of Data Sources
3 Executive Summary
4 Global Inhaled Antibiotics Market Outlook: 4.1 Overview; 4.2 Market Dynamics; 4.2.1 Drivers; 4.2.2 Restraints; 4.2.3 Opportunities; 4.3 Porters Five Force Model; 4.4 Value Chain Analysis
5 Global Inhaled Antibiotics Market, By Product Type: 5.1 Y-o-Y Growth Comparison, By Product Type; 5.2 Global Inhaled Antibiotics Market Share Analysis, By Product Type; 5.3 Global Inhaled Antibiotics Market Size and Forecast, By Product Type; 5.3.1 Aerosol; 5.3.2 Dry Powder Formulation; 5.3.3 Spray
6 Global Inhaled Antibiotics Market, By Application: 6.1 Y-o-Y Growth Comparison, By Application; 6.2 Global Inhaled Antibiotics Market Share Analysis, By Application; 6.3 Global Inhaled Antibiotics Market Size and Forecast, By Application; 6.3.1 Pneumonia; 6.3.2 Asthma; 6.3.3 Bronchitis; 6.3.4 Others
7 Global Inhaled Antibiotics Market, By Distribution Channel: 7.1 Y-o-Y Growth Comparison, By Distribution Channel; 7.2 Global Inhaled Antibiotics Market Share Analysis, By Distribution Channel; 7.3 Global Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 7.3.1 Retail Pharmacies; 7.3.2 Hospital Pharmacies; 7.3.3 Online Pharmacies
8 Global Inhaled Antibiotics Market, By Region: 8.1 Global Inhaled Antibiotics Market Share Analysis, By Region; 8.2 Global Inhaled Antibiotics Market Share Analysis, By Region; 8.3 Global Inhaled Antibiotics Market Size and Forecast, By Region
9 North America Inhaled Antibiotics Market Analysis and Forecast (2020-2027): 9.1 Introduction; 9.2 North America Inhaled Antibiotics Market Share Analysis, By Product Type; 9.3 North America Inhaled Antibiotics Market Size and Forecast, By Application; 9.4 North America Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 9.5 North America Inhaled Antibiotics Market Size and Forecast, By Country; 9.5.1 U.S.; 9.5.2 Canada; 9.5.3 Mexico
10 EuropeInhaled Antibiotics Market Analysis and Forecast (2020-2027): 10.1 Introduction; 10.2 Europe Inhaled Antibiotics Market Share Analysis, By Product Type; 10.3 Europe Inhaled Antibiotics Market Size and Forecast, By Application; 10.4 Europe Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 10.5 Europe Inhaled Antibiotics Market Size and Forecast, By Country; 10.5.1 Germany; 10.5.2 France; 10.5.3 UK; 10.5.4 Rest of Europe
11 Asia Pacific Inhaled Antibiotics Market Analysis and Forecast (2020-2027): 11.1 Introduction; 11.2 Asia Pacific Inhaled Antibiotics Market Share Analysis, By Product Type; 11.3 Asia Pacific Inhaled Antibiotics Market Size and Forecast, By Application; 11.4 Asia Pacific Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 11.5 Asia Pacific Inhaled Antibiotics Market Size and Forecast, By Country; 11.5.1 China; 11.5.2 Japan; 11.5.3 India; 11.5.4 Rest of Asia Pacific
12 Latin America Inhaled Antibiotics Market Analysis and Forecast (2020-2027): 12.1 Introduction; 12.2 Latin America Inhaled Antibiotics Market Share Analysis, By Product Type; 12.3 Latin America Inhaled Antibiotics Market Size and Forecast, By Application; 12.4 Latin America Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 12.5 Latin America Inhaled Antibiotics Market Size and Forecast, Country
13 Middle East Inhaled Antibiotics Market Analysis and Forecast (2020-2027): 13.1 Introduction; 13.2 Middle East Inhaled Antibiotics Market Share Analysis, By Product Type; 13.3 Middle East Inhaled Antibiotics Market Size and Forecast, By Application; 13.4 Middle East Inhaled Antibiotics Market Size and Forecast, By Distribution Channel; 13.5 Middle East Inhaled Antibiotics Market Size and Forecast, By Country
14 Competitive Analysis: 14.1 Competition Dashboard; 14.2 Market share Analysis of Top Vendors; 14.3 Key Development Strategies
15 Company Profiles: 15.1 Lupin Ltd; 15.1.1 Overview; 15.1.2 Offerings; 15.1.3 Key Financials; 15.1.4 Business Segment & Geographic Overview; 15.1.5 Key Market Developments; 15.1.6 Key Strategies; 15.2.Polyphor; 15.2.1 Overview; 15.2.2 Offerings; 15.2.3 Key Financials; 15.2.4 Business Segment & Geographic Overview; 15.2.5 Key Market Developments; 15.2.6 Key Strategies; 15.3. Aradigm; 15.3.1 Overview; 15.3.2 Offerings; 15.3.3 Key Financials; 15.3.4 Business Segment & Geographic Overview; 15.3.5 Key Market Developments; 15.3.6 Key Strategies; 15.4 Gilead Sciences; 15.4.1 Overview; 15.4.2 Offerings; 15.4.3 Key Financials; 15.4.4 Business Segment & Geographic Overview; 15.4.5 Key Market Developments; 15.4.6 Key Strategies; 15.5 Insmed Incorporated; 15.5.1 Overview; 15.5.2 Offerings; 15.5.3 Key Financials; 15.5.4 Business Segment & Geographic Overview; 15.5.5 Key Market Developments; 15.5.6 Key Strategies; 15.6 Pharmaero; 15.6.1 Overview; 15.6.2 Offerings; 15.6.3 Key Financials; 15.6.4 Business Segment & Geographic Overview; 15.6.5 Key Market Developments; 15.6.6 Key Strategies; 15.7 Joincare Pharmaceutical Group; 15.7.1 Overview; 15.7.2 Offerings; 15.7.3 Key Financials; 15.7.4 Business Segment & Geographic Overview; 15.7.5 Key Market Developments; 15.7.6 Key Strategies; 15.8 Savara Pharmaceuticals; 15.8.1 Overview; 15.8.2 Offerings; 15.8.3 Key Financials; 15.8.4 Business Segment & Geographic Overview; 15.8.5 Key Market Developments; 15.8.6 Key Strategies; 15.9 Pharmaxis Ltd; 15.9.1 Overview; 15.9.2 Offerings; 15.9.3 Key Financials; 15.9.4 Business Segment & Geographic Overview; 15.9.5 Key Market Developments; 15.9.6 Key Strategies